Home › Funds › Trails Edge Capital Partners, LP › CLDX
Trails Edge Capital Partners, LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Trails Edge Capital Partners, LP reported holding 765,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$24.8M, representing 3.56% of its reported portfolio and ranking #13 among its reported holdings. Trails Edge Capital Partners, LP first reported this position in Q3 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's CLDX position evolved
Trails Edge Capital Partners, LP first disclosed a stake in CLDX in Q3 2026 at 765,000 shares (US$24.8M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 765.00K | $24.79M | New |
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 39 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), Deep Track Capital, LP (US$68.9M), EVENTIDE ASSET MANAGEMENT, LLC (US$61.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- Deep Track Capital, LP 2.13M sh · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- ADAR1 Capital Management, LLC 799.30K sh · $25.91M · Q3 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held CLDX?
Trails Edge Capital Partners, LP has disclosed CLDX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Trails Edge Capital Partners, LP's current position in CLDX?
As of Q3 2026, Trails Edge Capital Partners, LP holds 765.00K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $24.79M, representing 3.56% of its reported portfolio and ranking #13.
Has Trails Edge Capital Partners, LP been buying or selling CLDX?
In the latest 13F filing (Q3 2026), Trails Edge Capital Partners, LP newly opened its position in CLDX.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, EVENTIDE ASSET MANAGEMENT, LLC, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.